DiscGenics
Founded Year
2007Stage
Series C | AliveTotal Raised
$66.52MLast Raised
$50M | 3 yrs agoAbout DiscGenics
DiscGenics is a spinal therapeutics company using adult human disc-derived stem cells and tissue engineering techniques to treat patients debilitated by degenerative disc disease (DDD).
Missing: DiscGenics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: DiscGenics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing DiscGenics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
DiscGenics is included in 4 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Health IT
7,901 items
DiscGenics Patents
DiscGenics has filed 10 patents.
The 3 most popular patent topics include:
- Biotechnology
- Bones of the vertebral column
- Cell biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/8/2016 | 11/9/2021 | Bones of the vertebral column, Skeletal system, Annular solar eclipses, Orthopedic surgical procedures, Neurosurgery | Grant |
Application Date | 11/8/2016 |
|---|---|
Grant Date | 11/9/2021 |
Title | |
Related Topics | Bones of the vertebral column, Skeletal system, Annular solar eclipses, Orthopedic surgical procedures, Neurosurgery |
Status | Grant |
Latest DiscGenics News
Feb 28, 2023
News provided by Share this article Share this article SALT LAKE CITY, Feb. 28, 2023 /PRNewswire/ -- DiscGenics , Inc., a privately held, clinical stage biopharmaceutical company focused on developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it will present at Canaccord Genuity's 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023. DiscGenics's Chief Executive Officer and Chairman, Flagg Flanagan will present from 3:00 – 3:25 PM Pacific Time in Pompeian 4 at Caesars Palace Las Vegas. Flanagan will provide a corporate overview and update of the Company's recently completed clinical study of its allogeneic disc progenitor cell therapy (IDCT) for lumbar disc degeneration. About DiscGenics DiscGenics is a privately held, clinical-stage biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics's first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, mild to moderate lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain. For more information, visit discgenics.com . SOURCE DiscGenics, Inc.
DiscGenics Frequently Asked Questions (FAQ)
When was DiscGenics founded?
DiscGenics was founded in 2007.
Where is DiscGenics's headquarters?
DiscGenics's headquarters is located at 675 Arapeen Dr, Ste. 106, Salt Lake City.
What is DiscGenics's latest funding round?
DiscGenics's latest funding round is Series C.
How much did DiscGenics raise?
DiscGenics raised a total of $66.52M.
Who are the investors of DiscGenics?
Investors of DiscGenics include Mitsubishi UFJ Capital, Medical Incubator Japan, Ci:z Holdings, Eagle Private Capital, CareNet and 3 more.
Who are DiscGenics's competitors?
Competitors of DiscGenics include EpiBone.
Compare DiscGenics to Competitors
Regeneus is a biotechnology company. The company develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain. It is based in Paddington, New South Wales.
BioLab Sciences is a biotechnology company that does research on body healing and cell regeneration. It is based in Scottsdale, Arizona.
Novadip is a biopharmaceutical company founded to design, develop, and bring to the market stem cell-based therapies for regenerative medicine. The company's first proprietary cellular therapy is a differentiated and 3D osteogenic scaffold-free structure that provides treatments for severe bone healing disorders. The company was founded in 2013 and is based in Mont-Saint-Guilbert, Belgium.
Videregen offers a commercially available organ replacement product to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient's own stem cells are added, creating a bespoke organ replacement.
Novo Biosciences is a regenerative medicine company that develops small molecule therapies that reactivate and stimulate innate healing abilities in humans and animals.
EpiBone develops technology to create bone tissue from a patient's mesenchymal stem cells in vitro for use in bone grafts. Its technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like bone graft. The company was founded in 2013 and is based in Brooklyn, New York.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.